Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Prostate

Retrieve available abstracts of 333 articles:
HTML format

Single Articles

    August 2022
  1. WANG S, Ryan Russell J, Drescher M, Park A, et al
    Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
    PubMed     Abstract available

  2. LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
    Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
    PubMed     Abstract available

  3. KWAN EM, Wyatt AW
    Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
    Prostate. 2022;82 Suppl 1:S25-S36.
    PubMed     Abstract available

  4. SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
    Genomic biomarkers to guide precision radiotherapy in prostate cancer.
    Prostate. 2022;82 Suppl 1:S73-S85.
    PubMed     Abstract available

  5. KHAN HM, Cheng HH
    Germline genetics of prostate cancer.
    Prostate. 2022;82 Suppl 1:S3-S12.
    PubMed     Abstract available

    Clinical implications of homologous recombination repair mutations in prostate cancer.
    Prostate. 2022;82 Suppl 1:S45-S59.
    PubMed     Abstract available

  7. COTTER K, Rubin MA
    The evolving landscape of prostate cancer somatic mutations.
    Prostate. 2022;82 Suppl 1:S13-S24.
    PubMed     Abstract available

    Genetics and genomics of prostate cancer and therapeutic implications.
    Prostate. 2022;82 Suppl 1:S1-S2.

  9. MIZUNO K, Beltran H
    Future directions for precision oncology in prostate cancer.
    Prostate. 2022;82 Suppl 1:S86-S96.
    PubMed     Abstract available

    PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Prostate. 2022;82 Suppl 1:S60-S72.
    PubMed     Abstract available

  11. LI G, Xia YF, Huang YX, Okat D, et al
    Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
    PubMed     Abstract available

  12. UCAR T, Gunduz N, Demirci E, Culpan M, et al
    Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
    PubMed     Abstract available

    July 2022
  13. YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
    Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
    Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
    PubMed     Abstract available

  14. KHAN S, Vohra S, Farnan L, Elmore SNC, et al
    Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
    Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
    PubMed     Abstract available

  15. WANG Y, Tang Y, Gao X, Gan Y, et al
    Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
    Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
    PubMed     Abstract available

  16. MIYAHIRA AK, Soule HR
    The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
    PubMed     Abstract available

  17. MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
    A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
    PubMed     Abstract available

  18. RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
    Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
    PubMed     Abstract available

    June 2022
  19. YANAGISAWA T, Kimura T, Hata K, Narita S, et al
    Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
    PubMed     Abstract available

  20. CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
    Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
    PubMed     Abstract available

  21. BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
    Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
    PubMed     Abstract available

  22. MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
    Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
    PubMed     Abstract available

  23. YANG T, Liu Y, Chen S, Tian J, et al
    Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
    PubMed     Abstract available

  24. HEARD JR, Huang AJ, Werle L, Adler K, et al
    Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
    PubMed     Abstract available

  25. STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
    The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
    PubMed     Abstract available

  26. LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
    PubMed     Abstract available

  27. SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
    Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
    PubMed     Abstract available

  28. CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
    Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
    PubMed     Abstract available

  29. ABDI B, Basset N, Perrot E, Benderra MA, et al
    DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
    PubMed     Abstract available

  30. MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
    Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
    Prostate. 2022;82:933-941.
    PubMed     Abstract available

  31. FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
    Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
    Prostate. 2022;82:904-910.
    PubMed     Abstract available

  32. HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
    Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
    Prostate. 2022;82:894-903.
    PubMed     Abstract available

  33. RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
    Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
    Prostate. 2022;82:970-983.
    PubMed     Abstract available

    May 2022
  34. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    PubMed     Abstract available

  35. PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
    Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
    Prostate. 2022 May 10. doi: 10.1002/pros.24368.
    PubMed     Abstract available

  36. HE Y, Shen Q, Fu W, Wang H, et al
    Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    Prostate. 2022 May 10. doi: 10.1002/pros.24365.
    PubMed     Abstract available

  37. MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
    Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
    Prostate. 2022 May 10. doi: 10.1002/pros.24369.
    PubMed     Abstract available

    Orphan receptors in prostate cancer.
    Prostate. 2022 May 10. doi: 10.1002/pros.24370.
    PubMed     Abstract available

  39. KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
    Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
    Prostate. 2022 May 10. doi: 10.1002/pros.24363.
    PubMed     Abstract available

  40. DENMEADE S, Antonarakis ES, Markowski MC
    Bipolar androgen therapy (BAT): A patient's guide.
    Prostate. 2022;82:753-762.
    PubMed     Abstract available

  41. VITEK RA, Huang W, Geiger PG, Heninger E, et al
    Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
    Prostate. 2022;82:836-849.
    PubMed     Abstract available

  42. LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
    Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
    Prostate. 2022;82:804-808.
    PubMed     Abstract available

    April 2022
  43. BOSLAND MC, Horton L, Condon MS
    Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
    Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
    PubMed     Abstract available

  44. WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
    Current and projected number of years of life lost due to prostate cancer: A global study.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
    PubMed     Abstract available

  45. WANG M, Qi J, George AK, Semerjian A, et al
    The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
    PubMed     Abstract available

  46. HU Q, Hong X, Xu L, Jia R, et al
    A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
    PubMed     Abstract available

  47. YUEN KC, Tran B, Anton A, Hamidi H, et al
    Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
    Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
    PubMed     Abstract available

  48. PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
    Prostate cancer awareness among transgender women after gender-affirming surgery.
    Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
    PubMed     Abstract available

  49. MORI JO, Shafran JS, Stojanova M, Katz MH, et al
    Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
    PubMed     Abstract available

  50. FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
    Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
    PubMed     Abstract available

  51. LV X, Li Y, Li R, Guan X, et al
    Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
    PubMed     Abstract available

  52. SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
    Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
    PubMed     Abstract available

  53. YAMAGUCHI M, Murata T, Ramos JW
    Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
    PubMed     Abstract available

  54. ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
    Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Prostate. 2022;82:556-565.
    PubMed     Abstract available

  55. CHEN Z, Wu J, Sun K, He Y, et al
    Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
    Prostate. 2022;82:566-575.
    PubMed     Abstract available

  56. LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
    Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Prostate. 2022;82:576-583.
    PubMed     Abstract available

  57. WEI X, Roudier MP, Kwon OJ, Lee JD, et al
    Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
    Prostate. 2022;82:517-530.
    PubMed     Abstract available

    March 2022
  58. GRAHAM LS, Schweizer MT
    Mismatch repair deficiency and clinical implications in prostate cancer.
    Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
    PubMed     Abstract available

  59. PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
    Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
    Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
    PubMed     Abstract available

  60. SINGH CK, Denu RA, Nihal M, Shabbir M, et al
    PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
    Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
    PubMed     Abstract available

  61. MAO F, Kong Y, Liu J, Rao X, et al
    Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
    Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
    PubMed     Abstract available

  62. LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
    Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
    Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
    PubMed     Abstract available

  63. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
    PubMed     Abstract available

  64. ZHANG T, Kephart J, Bronson E, Anand M, et al
    Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
    PubMed     Abstract available

  65. ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
    Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
    PubMed     Abstract available

  66. SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
    Immune mechanisms behind prostate cancer in men of African ancestry: A review.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
    PubMed     Abstract available

  67. BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
    Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
    PubMed     Abstract available

  68. HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
    Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
    Prostate. 2022;82:405-414.
    PubMed     Abstract available

  69. LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
    Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:493-501.
    PubMed     Abstract available

  70. KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
    Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
    Prostate. 2022;82:425-432.
    PubMed     Abstract available

    February 2022
  71. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
    PubMed     Abstract available

  72. PURAYIL HT, Daaka Y
    betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
    PubMed     Abstract available

  73. LIU JM, Chen YT, Wu CT, Hsu WL, et al
    Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
    PubMed     Abstract available

  74. K C M, Oral E, Rung AL, Trapido EJ, et al
    Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
    Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
    PubMed     Abstract available

  75. KANEKO M, Fukuda N, Nagano H, Yamada K, et al
    Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
    Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
    PubMed     Abstract available

  76. IZOL V, Ok F, Aslan G, Akdogan B, et al
    Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
    PubMed     Abstract available

  77. OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
    Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
    PubMed     Abstract available

  78. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
    PubMed     Abstract available

  79. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
    PubMed     Abstract available

  80. PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
    Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
    PubMed     Abstract available

  81. WANG Y, Abenojar EC, Wang J, de Leon AC, et al
    Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
    PubMed     Abstract available

  82. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    PubMed     Abstract available

  83. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2022;82:401-402.

  84. URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
    Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
    Prostate. 2022;82:330-344.
    PubMed     Abstract available

  85. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
    Prostate. 2022;82:399-400.

  86. HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
    Don't throw the baby out with the bath water.
    Prostate. 2022;82:397-398.

  87. MA C, Downes M, Jain R, Ientilucci M, et al
    Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Prostate. 2022;82:345-351.
    PubMed     Abstract available

  88. ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
    Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
    Prostate. 2022;82:306-313.
    PubMed     Abstract available

  89. ARCOT R, Cher ML, Qi J, Linsell SM, et al
    Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Prostate. 2022;82:323-329.
    PubMed     Abstract available

  90. TAN YG, Fang AHS, Lim JKS, Khalid F, et al
    Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
    Prostate. 2022;82:298-305.
    PubMed     Abstract available

  91. MA H, Xu W, Ni J, Zhao N, et al
    Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Prostate. 2022;82:276-285.
    PubMed     Abstract available

  92. LI N, Song WJ, Gao J, Xu ZP, et al
    The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:221-226.
    PubMed     Abstract available

  93. AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
    Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
    Prostate. 2022;82:235-244.
    PubMed     Abstract available

  94. SIEDOW M, Eisner M, Yaney A, Washington I, et al
    Impact of prostate biopsy secondary pathology review on radiotherapy management.
    Prostate. 2022;82:210-215.
    PubMed     Abstract available

    January 2022
  95. LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
    Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
    PubMed     Abstract available

  96. GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
    Protein signatures to distinguish aggressive from indolent prostate cancer.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
    PubMed     Abstract available

  97. ZHAO R, Lv Y, Feng T, Zhang R, et al
    ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
    PubMed     Abstract available

  98. STOVER EH, Oh C, Keskula P, Choudhury AD, et al
    Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
    Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
    PubMed     Abstract available

  99. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    PubMed     Abstract available

  100. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    PubMed     Abstract available

  101. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    PubMed     Abstract available

  102. CAO Y, Song DY, Deville C, DeWeese TL, et al
    Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
    Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
    PubMed     Abstract available

  103. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    PubMed     Abstract available

  104. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    PubMed     Abstract available

  105. SEREF C, Acar O, Kilic M, Vural M, et al
    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
    Prostate. 2022;82:145-153.
    PubMed     Abstract available

  106. YUAN W, Liu B, Sanda M, Wei R, et al
    Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
    Prostate. 2022;82:132-144.
    PubMed     Abstract available

  107. WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
    Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
    Prostate. 2022;82:86-96.
    PubMed     Abstract available

    December 2021
  108. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    PubMed     Abstract available

  109. MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
    MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
    Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
    PubMed     Abstract available

  110. SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
    Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
    Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
    PubMed     Abstract available

  111. HE H, Han D, Xu F, Lyu J, et al
    How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
    PubMed     Abstract available

  112. URABE F, Miki K, Kimura T, Sasaki H, et al
    Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
    PubMed     Abstract available

  113. KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
    Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
    PubMed     Abstract available

  114. BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
    Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
    PubMed     Abstract available

  115. LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
    Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
    PubMed     Abstract available

  116. POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
    Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
    PubMed     Abstract available

  117. ZAREI A, Javid H, Sanjarian S, Senemar S, et al
    Metagenomics studies for the diagnosis and treatment of prostate cancer.
    Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
    PubMed     Abstract available

  118. MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
    The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
    Prostate. 2021;81:1428-1434.
    PubMed     Abstract available

  119. NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
    Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
    Prostate. 2021;81:1355-1364.
    PubMed     Abstract available

  120. YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
    Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Prostate. 2021;81:1402-1410.
    PubMed     Abstract available

  121. TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
    The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
    Prostate. 2021;81:1287-1293.
    PubMed     Abstract available

  122. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
    Prostate. 2021;81:1294-1302.
    PubMed     Abstract available

    November 2021
  123. NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
    Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
    PubMed     Abstract available

  124. VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
    Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
    PubMed     Abstract available

  125. PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
    Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
    PubMed     Abstract available

  126. PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
    Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
    PubMed     Abstract available

  127. NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
    Clinical and genomic features of SPOP-mutant prostate cancer.
    Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
    PubMed     Abstract available

  128. TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
    Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
    PubMed     Abstract available

  129. HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
    Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
    PubMed     Abstract available

  130. MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
    Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
    PubMed     Abstract available

    October 2021
  131. SHI Z, Lu L, Resurreccion WK, Yang W, et al
    Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
    PubMed     Abstract available

  132. PILLING A, Kim SH, Hwang C
    Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
    PubMed     Abstract available

  133. LUO LS, Jiang JF, Luan HH, Zi H, et al
    Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
    PubMed     Abstract available

  134. KIM S, Li L, Zhang J, Jiang C, et al
    Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
    PubMed     Abstract available

  135. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
    PubMed     Abstract available

  136. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
    PubMed     Abstract available

  137. IKEUCHI W, Wakita Y, Zhang G, Li C, et al
    AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
    PubMed     Abstract available

  138. JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
    Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
    PubMed     Abstract available

  139. PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
    The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
    Prostate. 2021;81:1064-1070.
    PubMed     Abstract available

    September 2021
  140. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    PubMed     Abstract available

  141. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    PubMed     Abstract available

  142. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    PubMed     Abstract available

  143. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    PubMed     Abstract available

  144. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    PubMed     Abstract available

  145. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
    PubMed     Abstract available

  146. JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
    Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
    PubMed     Abstract available

  147. LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
    Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
    PubMed     Abstract available

  148. AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
    The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
    PubMed     Abstract available

  149. WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
    PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
    PubMed     Abstract available

  150. LIU Y, Dong Y, Liu J, Zhang X, et al
    Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
    PubMed     Abstract available

  151. CHHATRE S, Malkowicz SB, Jayadevappa R
    Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
    PubMed     Abstract available

  152. SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
    Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
    PubMed     Abstract available

  153. CHO MC, Yoo S, Choo MS, Son H, et al
    Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
    PubMed     Abstract available

  154. MANGOSH TL, Grabowska MM, Taylor DJ
    SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
    PubMed     Abstract available

  155. MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
    Pathological significance and prognostic role of LATS2 in prostate cancer.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
    PubMed     Abstract available

  156. MIYAHIRA AK, Soule HR
    The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
    PubMed     Abstract available

  157. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
    PubMed     Abstract available

  158. EKSI M, Evren I, Akkas F, Arikan Y, et al
    Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
    Prostate. 2021;81:913-920.
    PubMed     Abstract available

  159. IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
    Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Prostate. 2021;81:866-873.
    PubMed     Abstract available

  160. MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
    Impact of median lobe on urinary function after robotic prostatectomy.
    Prostate. 2021;81:832-837.
    PubMed     Abstract available

  161. LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
    Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
    Prostate. 2021;81:1009-1017.
    PubMed     Abstract available

  162. SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
    Stromal cell interplay in prostate development, physiology, and pathological conditions.
    Prostate. 2021;81:926-937.
    PubMed     Abstract available

  163. WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
    Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
    Prostate. 2021;81:938-943.
    PubMed     Abstract available

    August 2021
  164. LEDET EM, Sartor O
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.

  165. DI MAIDA F, Grosso AA, Minervini A
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.

  166. SHAO L, Wang J, Karatas O, Ittmann M, et al
    MEX3D is an oncogenic driver in prostate cancer.
    Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
    PubMed     Abstract available

  167. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    PubMed     Abstract available

  168. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    PubMed     Abstract available

  169. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    PubMed     Abstract available

  170. HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
    Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
    PubMed     Abstract available

  171. WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
    The effect of primary urological cancers on survival in men with secondary prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
    PubMed     Abstract available

  172. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    PubMed     Abstract available

  173. WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
    Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
    Prostate. 2021;81:785-793.
    PubMed     Abstract available

  174. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
    Prostate. 2021;81:778-784.
    PubMed     Abstract available

  175. WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
    Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
    Prostate. 2021;81:772-777.
    PubMed     Abstract available

    July 2021
  176. ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
    Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
    PubMed     Abstract available

  177. LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
    Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
    PubMed     Abstract available

  178. CAO Y, Zhang W, Li Y, Fu J, et al
    Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
    PubMed     Abstract available

  179. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
    Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
    PubMed     Abstract available

  180. CHAO OS, Goodman OB Jr
    DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
    PubMed     Abstract available

    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.

  182. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed     Abstract available

  183. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed     Abstract available

  184. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed     Abstract available

  185. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed     Abstract available

  186. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed     Abstract available

  187. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    PubMed     Abstract available

  188. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    PubMed     Abstract available

  189. CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
    Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
    Prostate. 2021;81:694-702.
    PubMed     Abstract available

    June 2021
  190. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    PubMed     Abstract available

  191. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    PubMed     Abstract available

  192. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    PubMed     Abstract available

  193. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    PubMed     Abstract available

  194. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    PubMed     Abstract available

  195. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed     Abstract available

  196. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed     Abstract available

  197. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available

  198. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available

  199. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
    Prostate. 2021;81:443-451.
    PubMed     Abstract available

  200. CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
    Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
    Prostate. 2021;81:521-529.
    PubMed     Abstract available

  201. XIAO GQ, Ho G, Suen C, Hurth KM, et al
    Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Prostate. 2021;81:469-477.
    PubMed     Abstract available

    May 2021
  202. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed     Abstract available

  203. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed     Abstract available

  204. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed     Abstract available

  205. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed     Abstract available

  206. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed     Abstract available

  207. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed     Abstract available

  208. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.

  209. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available

  210. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available

  211. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available

  212. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available

  213. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available

  214. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available

  215. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available

  216. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    PubMed     Abstract available

  217. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    PubMed     Abstract available

  218. ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
    Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Prostate. 2021;81:390-397.
    PubMed     Abstract available

    April 2021
  219. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available

  220. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available

  221. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available

  222. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available

  223. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available

  224. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available

  225. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available

  226. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available

  227. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available

  228. LEDET EM, Burgess EF, Sokolova AO, Jaeger EB, et al
    Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Prostate. 2021 Apr 1. doi: 10.1002/pros.24123.
    PubMed     Abstract available

    March 2021
  229. SABOL RA, Ledet EM, Jaeger E, Hatton W, et al
    Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Prostate. 2021 Mar 24. doi: 10.1002/pros.24120.
    PubMed     Abstract available

  230. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    What are survivorship care plans failing to tell men after prostate cancer treatment?
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24116.
    PubMed     Abstract available

  231. GRAHAM LS, True LD, Gulati R, Schade GR, et al
    Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
    Prostate. 2021 Mar 23. doi: 10.1002/pros.24118.
    PubMed     Abstract available

  232. LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
    Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
    PubMed     Abstract available

  233. LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
    Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
    PubMed     Abstract available

  234. ZHENG X, Xu H, Gong L, Cao D, et al
    Vinculin orchestrates prostate cancer progression by regulating tumor cell invasion, migration, and proliferation.
    Prostate. 2021 Mar 12. doi: 10.1002/pros.24113.
    PubMed     Abstract available

  235. ATEEQ B, Kunju LP, Carskadon SL, Pandey SK, et al
    Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Prostate. 2021 Mar 8. doi: 10.1002/pros.24111.

  236. SWANSON GP, Lenz L, Stone S, Cohen T, et al
    Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Prostate. 2021;81:261-267.
    PubMed     Abstract available

  237. TAN YG, Khalid F, Huang HH, Chen K, et al
    Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Prostate. 2021;81:242-251.
    PubMed     Abstract available

  238. LI Y, Ge C, Franceschi RT
    Role of Runx2 in prostate development and stem cell function.
    Prostate. 2021;81:231-241.
    PubMed     Abstract available

    February 2021
  239. SHENDEROV E, Boudadi K, Fu W, Wang H, et al
    Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Prostate. 2021 Feb 26. doi: 10.1002/pros.24110.
    PubMed     Abstract available

  240. WETTSTEIN MS, David LA, Pazhepurackel C, Qureshi AA, et al
    Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
    Prostate. 2021 Feb 18. doi: 10.1002/pros.24105.
    PubMed     Abstract available

  241. TAO LJ, Pan XY, Wang JW, Zhang L, et al
    Circular RNA circANKS1B acts as a sponge for miR-152-3p and promotes prostate cancer progression by upregulating TGF-alpha expression.
    Prostate. 2021 Feb 8. doi: 10.1002/pros.24102.
    PubMed     Abstract available

  242. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    PubMed     Abstract available

    January 2021
  243. NAITO R, Kano H, Shimada T, Makino T, et al
    A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Prostate. 2021 Jan 25. doi: 10.1002/pros.24106.
    PubMed     Abstract available

  244. EMAM A, Hermann G, Attwood K, Ji W, et al
    Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer.
    Prostate. 2021 Jan 20. doi: 10.1002/pros.24089.
    PubMed     Abstract available

  245. VLACHOSTERGIOS PJ, Niaz MJ, Skafida M, Mosallaie SA, et al
    Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted beta-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jan 19. doi: 10.1002/pros.24104.
    PubMed     Abstract available

  246. LIU JM, Lin CC, Chen MF, Liu KL, et al
    Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
    Prostate. 2021 Jan 4. doi: 10.1002/pros.24096.
    PubMed     Abstract available

  247. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available

    December 2020
  248. IMAMURA R, Kitagawa S, Kubo T, Irie A, et al
    Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Prostate. 2020 Dec 24. doi: 10.1002/pros.24090.
    PubMed     Abstract available

  249. COUGHLIN SS, Vernon M, Klaassen Z, Tingen MS, et al
    Knowledge of prostate cancer among African American men: A systematic review.
    Prostate. 2020 Dec 23. doi: 10.1002/pros.24097.
    PubMed     Abstract available

  250. KAZUNO S, Fujimura T, Fujime M, Miura Y, et al
    O-glycosylated clusterin as a sensitive marker for diagnosing early stages of prostate cancer.
    Prostate. 2020 Dec 21. doi: 10.1002/pros.24094.
    PubMed     Abstract available

  251. ZHANG Y, Mou Y, Liang C, Zhu S, et al
    Promoting cell proliferation, cell cycle progression, and glycolysis: Glycometabolism-related genes act as prognostic signatures for prostate cancer.
    Prostate. 2020 Dec 18. doi: 10.1002/pros.24092.
    PubMed     Abstract available

  252. ZHOU Y, Mai Z, Yan W, Chen Y, et al
    The characteristics and spatial distributions of prostate cancer in autopsy specimens.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24091.
    PubMed     Abstract available

  253. ZHANG Y, Guo Z, Du T, Chen J, et al
    Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
    Prostate. 2020 Dec 11. doi: 10.1002/pros.24093.

  254. SHEIKHBAHAEI S, Reyes DK, Rowe SP, Pienta KJ, et al
    CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naive oligometastatic prostate cancer.
    Prostate. 2020 Dec 1. doi: 10.1002/pros.24088.
    PubMed     Abstract available

  255. GREENLAND NY, Cowan JE, Chan E, Carroll PR, et al
    Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
    Prostate. 2020;80:1421-1428.
    PubMed     Abstract available

  256. LI W, Bicak M, Sjoberg DD, Vertosick E, et al
    Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
    Prostate. 2020;80:1405-1412.
    PubMed     Abstract available

    November 2020
  257. SHIH HJ, Fang SC, An L, Shao YJ, et al
    Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality.
    Prostate. 2020 Nov 5. doi: 10.1002/pros.24087.
    PubMed     Abstract available

  258. YAMOAH K, Lal P, Awasthi S, Naghavi AO, et al
    TMPRSS2-ERG fusion impact anterior tumor location in men with prostate cancer.
    Prostate. 2020 Nov 3. doi: 10.1002/pros.24086.
    PubMed     Abstract available

  259. DEEK M, Lilleby W, Vaage V, Hole KH, et al
    Impact of radiation dose on recurrence in high-risk prostate cancer patients.
    Prostate. 2020;80:1322-1327.
    PubMed     Abstract available

  260. BLACK MH, Li S, LaDuca H, Lo MT, et al
    Validation of a prostate cancer polygenic risk score.
    Prostate. 2020;80:1314-1321.
    PubMed     Abstract available

    October 2020
  261. JARRARD D, Filon M, Huang W, Havighurst T, et al
    A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
    Prostate. 2020 Oct 23. doi: 10.1002/pros.24076.
    PubMed     Abstract available

  262. YANG Y, Attwood K, Bshara W, Mohler JL, et al
    High intratumoral CD8(+) T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24068.
    PubMed     Abstract available

  263. MIYAHIRA AK, Soule HR
    The 26th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2020 Oct 21. doi: 10.1002/pros.24083.
    PubMed     Abstract available

  264. WASHINGTON SL 3RD, Cowan JE, Herlemann A, Zuniga KB, et al
    Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Prostate. 2020 Oct 19. doi: 10.1002/pros.24085.
    PubMed     Abstract available

  265. AMELOT A, Terrier LM, Le Nail LR, Cristini J, et al
    Spine metastasis in patients with prostate cancer: Survival prognosis assessment.
    Prostate. 2020 Oct 16. doi: 10.1002/pros.24084.
    PubMed     Abstract available

  266. IWAMOTO H, Izumi K, Shimada T, Kano H, et al
    Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
    PubMed     Abstract available

  267. DING Y, Lee M, Gao Y, Bu P, et al
    Neuropeptide Y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance.
    Prostate. 2020 Oct 6. doi: 10.1002/pros.24081.
    PubMed     Abstract available

  268. HERTZOG JR, Zhang Z, Bignan G, Connolly PJ, et al
    AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
    Prostate. 2020;80:1223-1232.
    PubMed     Abstract available

  269. MONTES M, MacKenzie L, McAllister MJ, Roseweir A, et al
    Determining the prognostic significance of IKKalpha in prostate cancer.
    Prostate. 2020;80:1188-1202.
    PubMed     Abstract available

    September 2020
  270. VICIER C, Ravi P, Kwak L, Werner L, et al
    Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
    PubMed     Abstract available

  271. OMRI N, Kamil M, Alexander K, Alexander K, et al
    Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Prostate. 2020 Sep 24. doi: 10.1002/pros.24078.
    PubMed     Abstract available

  272. LEE BS, Chu SY, Jung WJ, Jeong HJ, et al
    (18) F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
    Prostate. 2020 Sep 22. doi: 10.1002/pros.24062.
    PubMed     Abstract available

  273. VILSON FL, Li S, Brooks JD, Eisenberg ML, et al
    Sudden PSA rise to >/=20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
    Prostate. 2020 Sep 21. doi: 10.1002/pros.24075.
    PubMed     Abstract available

  274. HARSHMAN LC, Wang VX, Hamid AA, Santone G, et al
    Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
    Prostate. 2020 Sep 19. doi: 10.1002/pros.24074.
    PubMed     Abstract available

  275. NAITO Y, Kato M, Kawanishi H, Yuguchi Y, et al
    The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Prostate. 2020 Sep 11. doi: 10.1002/pros.24069.
    PubMed     Abstract available

  276. DUBEY B, Jackson M, Zeigler-Johnson C, Devarajan K, et al
    Interactive effect of TLR SNPs and exposure to sexually transmitted infections on prostate cancer risk in Jamaican men.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24067.
    PubMed     Abstract available

  277. ZHANG M, Wang Q, Sun X, Yin Q, et al
    beta2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation.
    Prostate. 2020 Sep 7. doi: 10.1002/pros.24060.
    PubMed     Abstract available

  278. KAUR H, Samarska I, Lu J, Faisal F, et al
    Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Prostate. 2020;80:1012-1023.
    PubMed     Abstract available

  279. ANGEL PM, Spruill L, Jefferson M, Bethard JR, et al
    Zonal regulation of collagen-type proteins and posttranslational modifications in prostatic benign and cancer tissues by imaging mass spectrometry.
    Prostate. 2020;80:1071-1086.
    PubMed     Abstract available

    August 2020
  280. MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
    PubMed     Abstract available

  281. MCALLISTER M, Constancio V, Patek S, Gan H, et al
    Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naive prostate cancer.
    Prostate. 2020 Aug 26. doi: 10.1002/pros.24064.
    PubMed     Abstract available

  282. WIGGINS EK, Oyekunle T, Howard LE, Markt SC, et al
    Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial.
    Prostate. 2020 Aug 24. doi: 10.1002/pros.24052.
    PubMed     Abstract available

  283. LIU W, Hou J, Petkewicz J, Na R, et al
    Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Prostate. 2020 Aug 17. doi: 10.1002/pros.24057.
    PubMed     Abstract available

  284. SHORE ND, Drake CG, Lin DW, Ryan CJ, et al
    Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Prostate. 2020 Aug 11. doi: 10.1002/pros.24053.
    PubMed     Abstract available

  285. DI BELLA CM, Howard LE, Oyekunle T, De Hoedt AM, et al
    Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy.
    Prostate. 2020 Aug 7. doi: 10.1002/pros.24054.
    PubMed     Abstract available

  286. SIMONS BW, Dalrymple S, Rosen M, Zheng L, et al
    A hemi-spleen injection model of liver metastasis for prostate cancer.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24055.
    PubMed     Abstract available

  287. NAEEM A, Dakshanamurthy S, Walthieu H, Parasido E, et al
    Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells.
    Prostate. 2020 Aug 6. doi: 10.1002/pros.24050.
    PubMed     Abstract available

    July 2020
  288. AHMED ME, Andrews JR, Alamiri J, Higa J, et al
    Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
    PubMed     Abstract available

  289. NANDA JS, Awadallah WN, Kohrt SE, Popovics P, et al
    Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
    Prostate. 2020 Jul 21. doi: 10.1002/pros.24019.
    PubMed     Abstract available

  290. FERRARI MG, Ganaie AA, Shabenah A, Mansini AP, et al
    Identifying and treating ROBO1(-ve) /DOCK1(+ve) prostate cancer: An aggressive cancer subtype prevalent in African American patients.
    Prostate. 2020 Jul 20. doi: 10.1002/pros.24018.
    PubMed     Abstract available

  291. DEE EC, Nezolosky MD, Chipidza FE, Arega MA, et al
    Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
    Prostate. 2020 Jul 13. doi: 10.1002/pros.24041.
    PubMed     Abstract available

  292. ABUDUREXITI M, Zhu W, Wang Y, Wang J, et al
    Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Prostate. 2020 Jul 10. doi: 10.1002/pros.24027.
    PubMed     Abstract available

  293. ERICKSON AM, Lokman U, Lahdensuo K, Tornberg S, et al
    PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
    Prostate. 2020 Jul 7. doi: 10.1002/pros.24040.
    PubMed     Abstract available

  294. ZHAN B, Huang L, Chen Y, Ye W, et al
    miR-196a-mediated downregulation of p27(kip1) protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24036.
    PubMed     Abstract available

  295. FEDERER-GSPONER JR, Muller DC, Zellweger T, Eggimann M, et al
    Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24039.
    PubMed     Abstract available

  296. QIN C, Sheng Z, Huang X, Tang J, et al
    Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24042.
    PubMed     Abstract available

  297. BONK S, Kluth M, Jansen K, Hube-Magg C, et al
    Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
    Prostate. 2020 Jul 6. doi: 10.1002/pros.24038.
    PubMed     Abstract available

  298. TANG M, Gao S, Zhang L, Liu B, et al
    Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Prostate. 2020;80:742-752.
    PubMed     Abstract available

  299. RINELLA L, Pizzo B, Frairia R, Delsedime L, et al
    Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
    Prostate. 2020 Jul 1. doi: 10.1002/pros.24037.
    PubMed     Abstract available

    June 2020
  300. CHEN Y, Li X, Mamouni K, Yang Y, et al
    Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer.
    Prostate. 2020 Jun 19. doi: 10.1002/pros.24032.
    PubMed     Abstract available

  301. MAESHIGE N, Kitagawa K, Yamasaki S, Ishii A, et al
    Can ultrasound irradiation be a therapeutic option for prostate cancer?
    Prostate. 2020 Jun 18. doi: 10.1002/pros.24030.
    PubMed     Abstract available

  302. BEGEMANN D, Wang Y, Yang W, Kyprianou N, et al
    Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Prostate. 2020 Jun 16. doi: 10.1002/pros.24015.
    PubMed     Abstract available

  303. WANG K, Chen Z, Shi J, Feng Y, et al
    Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Prostate. 2020 Jun 15. doi: 10.1002/pros.24029.
    PubMed     Abstract available

  304. TAYLOR RA, Farrelly SG, Clark AK, Watt MJ, et al
    Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice.
    Prostate. 2020 Jun 10. doi: 10.1002/pros.24024.
    PubMed     Abstract available

  305. ELHODAKY M, Hong LK, Kadkol S, Diamond AM, et al
    Selenium-binding protein 1 alters energy metabolism in prostate cancer cells.
    Prostate. 2020 Jun 8. doi: 10.1002/pros.24028.
    PubMed     Abstract available

  306. CHADID S, Barber JR, Nelson WG, Gurel B, et al
    The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24023.
    PubMed     Abstract available

  307. CARSON JJK, Di Lena MA, Berman DM, Siemens DR, et al
    Development and initial clinical correlation of a DNA methylation-based blood test for prostate cancer.
    Prostate. 2020 Jun 7. doi: 10.1002/pros.24025.
    PubMed     Abstract available

  308. RII J, Sakamoto S, Yamada Y, Takeshita N, et al
    Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Prostate. 2020 Jun 5. doi: 10.1002/pros.24016.
    PubMed     Abstract available

  309. CHEN X, Chen F, Ren Y, Weng G, et al
    Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer.
    Prostate. 2020;80:727.

  310. OJALILL M, Virtanen N, Rappu P, Siljamaki E, et al
    Interaction between prostate cancer cells and prostate fibroblasts promotes accumulation and proteolytic processing of basement membrane proteins.
    Prostate. 2020;80:715-726.
    PubMed     Abstract available

  311. ITSUMI M, Shiota M, Sekino Y, Ushijima M, et al
    High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
    Prostate. 2020 Jun 1. doi: 10.1002/pros.24022.
    PubMed     Abstract available

  312. ELSHAFAE SM, Dirksen WP, Alasonyalilar-Demirer A, Breitbach J, et al
    Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Prostate. 2020;80:698-714.
    PubMed     Abstract available

  313. PALANGMONTHIP W, Wu R, Tarima S, Bobholz SA, et al
    Corpora amylacea in benign prostatic acini are associated with concurrent, predominantly low-grade cancer.
    Prostate. 2020;80:687-697.
    PubMed     Abstract available

    May 2020
  314. LINDER A, Larsson K, Welen K, Damber JE, et al
    RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Prostate. 2020 May 25. doi: 10.1002/pros.23994.
    PubMed     Abstract available

  315. TABEI T, Taguri M, Sakai N, Koh H, et al
    Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Prostate. 2020 May 20. doi: 10.1002/pros.23997.
    PubMed     Abstract available

  316. SHI X, Sun J, Li H, Lin H, et al
    Antitumor efficacy of interferon-gamma-modified exosomal vaccine in prostate cancer.
    Prostate. 2020 May 19. doi: 10.1002/pros.23996.
    PubMed     Abstract available

  317. HOU Y, Li H, Huo W
    THBS4 silencing regulates the cancer stem cell-like properties in prostate cancer via blocking the PI3K/Akt pathway.
    Prostate. 2020 May 18. doi: 10.1002/pros.23989.
    PubMed     Abstract available

  318. LIU Z, Murphy SF, Huang J, Zhao L, et al
    A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Prostate. 2020 May 14. doi: 10.1002/pros.23993.
    PubMed     Abstract available

  319. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association between dihydrotestosterone and long-term risk for prostate cancer mortality: A prospective cohort study.
    Prostate. 2020 May 5. doi: 10.1002/pros.23991.
    PubMed     Abstract available

  320. LIU S, Liu F, Zhang B, Yan P, et al
    CD4(+) T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion.
    Prostate. 2020 May 1. doi: 10.1002/pros.23990.
    PubMed     Abstract available

  321. SU X, Long Q, Bo J, Shi Y, et al
    Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
    Prostate. 2020;80:508-517.
    PubMed     Abstract available

  322. GLEAVE AM, Ci X, Lin D, Wang Y, et al
    A synopsis of prostate organoid methodologies, applications, and limitations.
    Prostate. 2020;80:518-526.
    PubMed     Abstract available

  323. GREENLAND NY, Cowan JE, Zhang L, Carroll PR, et al
    Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Prostate. 2020;80:653-659.
    PubMed     Abstract available

    April 2020
  324. SEBBEN M, Tafuri A, Porcaro AB, Artibani W, et al
    Response to: Bando et al. Diagnostic and therapeutic value of pelvic lymph node dissection in the fossa of Marcille in patients with clinically localized high-risk prostate cancer: Histological and molecular analyses.
    Prostate. 2020 Apr 23. doi: 10.1002/pros.23987.

  325. LI X, Jiao M, Hu J, Qi M, et al
    miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
    Prostate. 2020 Apr 15. doi: 10.1002/pros.23979.
    PubMed     Abstract available

  326. CHENG Y, Wang D, Jiang J, Huang W, et al
    Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Prostate. 2020 Apr 13. doi: 10.1002/pros.23976.
    PubMed     Abstract available

    March 2020
  327. LEU WJ, Wang CT, Hsu JL, Chen IS, et al
    Ascleposide, a natural cardenolide, induces anticancer signaling in human castration-resistant prostatic cancer through Na(+) /K(+) -ATPase internalization and tubulin acetylation.
    Prostate. 2020;80:305-318.
    PubMed     Abstract available

  328. WU Z, Wang K, Yang Z, Pascal LE, et al
    A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR(F876L) nuclear import and function.
    Prostate. 2020;80:319-328.
    PubMed     Abstract available

    February 2020
  329. ERDEM S, Verep S, Bagbudar S, Ozluk Y, et al
    The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Prostate. 2020;80:225-234.
    PubMed     Abstract available

  330. FAGERLAND ST, Hill DK, van Wamel A, de Lange Davies C, et al
    Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
    Prostate. 2020;80:186-197.
    PubMed     Abstract available

  331. TAYLOR AS, Morgan TM, Wallington DG, Chinnaiyan AM, et al
    Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Prostate. 2020;80:146-152.
    PubMed     Abstract available

  332. THOMAS-JARDIN SE, Dahl H, Kanchwala MS, Ha F, et al
    RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Prostate. 2020;80:133-145.
    PubMed     Abstract available

  333. WANG R, Lewis MS, Lyu J, Zhau HE, et al
    Cancer-stromal cell fusion as revealed by fluorescence protein tracking.
    Prostate. 2020;80:274-283.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.